Tandem Diabetes Closes Equity Offering

Represented Tandem Diabetes Care (NASDAQ: TNDM) in connection with an underwritten public offering, consisting of approximately 3.5 million shares of its common stock at a public offering price of $28.50 per share for proceeds of approximately $100 million along with a $15 million over-allotment option for gross proceeds of $115 million.

Tandem, based in San Diego, California, is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. Among other products, Tandem manufactures and sells the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.

The deal team representing Tandem included Bruce Feuchter, Ryan Wilkins, Sonya Attal and Peter Hong.

Please enable JavaScript, then refresh this page. JavaScript is required on this site.